title: Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension.
abstract: Maher has received grants, consulting fees, and speaker fees from GlaxoSmithKline and UCB and grants from Novartis. He has also received consulting fees and speaker fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, Lanthio, InterMune International AG (a wholly owned Roche subsidiary since 2014), F. Hoffmann-La Roche, Sanofi-Aventis, and Takeda. Maher is supported by a National Institute for Health Research Clinician Scientist Fellowship (NIHR Ref: CS:-2013-13-017). Dejonckheere is an employee of F. Hoffmann-La Roche. Nathan has received consulting fees from Roche-Genentech and Boehringer Ingelheim. He is also on the speakers bureau for Roche-Genentech and Boehringer Ingelheim and has received research funding from both companies. All authors contributed equally to study concept and design, data collection and analysis, and manuscript preparation.
authors.affiliation: 1 Interstitial Lung Disease Unit, Royal Brompton Hospital/Imperial College London, London, United Kingdom.
authors.forename: Toby M
authors.initials: TM
authors.lastname: Maher
authors.affiliation: 2 F. Hoffmann-La Roche, Basel, Switzerland.
authors.forename: Fred
authors.initials: F
authors.lastname: Dejonckheere
authors.affiliation: 3 Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, Virginia.
authors.forename: Steven D
authors.initials: SD
authors.lastname: Nathan
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D054990:Idiopathic Pulmonary Fibrosis / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D007211:Indoles / Q000627:therapeutic use; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D015996:Survival Rate / Q000639:trends
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007211:Indoles; D058986:Phosphodiesterase 5 Inhibitors; D011728:Pyridones; C093844:pirfenidone; C530716:nintedanib